Controversy

Whether MGMT promoter methylation can be reliably predicted from routine MRI

Evidence profile

Status: awaiting_review. Rule: atlas-profile-2.0.

7 linked publications; not a count of independent studies.

Missing appraisal does not mean no evidence exists. Inspect the full profile and source relationships in the interactive Atlas.

Historical grade: WEAK (retained from 22 September 2026; not a completed profile 2.0 assessment).

Position A

Multiple ML/DL models report AUCs 0.7-0.9 for MGMT prediction on multiparametric MRI

Position B

Well-designed studies conclude MRI cannot reliably predict MGMT; BraTS-MGMT-style tasks show near-chance external performance; positive results attributed to leakage/overfitting

Clinical stakes

MGMT governs temozolomide benefit; a false imaging surrogate could misdirect therapy or trial stratification

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Editorial lead: Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Page generated 2026-10-02. This is not a new clinical review date.

This is an educational research resource from Resonant Labs, not clinical advice. Atlas assessments are heuristic, not probabilities or formal GRADE ratings. Findings are summarized from the literature and may change as the field evolves.